You are viewing the site in preview mode

Skip to main content
Fig. 1 | Virology Journal

Fig. 1

From: Effectiveness of azvudine versus nirmatrelvir/ritonavir for hospitalized patients with SARS-CoV-2 infection and pre-existing liver diseases

Fig. 1

The cohort flow diagram. A Study population flowchart showing the inclusion and exclusion of Azvudine recipients and Paxlovid recipients among hospitalized patients with COVID-19 and pre-existing chronic liver diseases during the study period. B Baseline characteristics of the study population before and after 2:1 propensity score matching

Back to article page

Virology Journal

ISSN: 1743-422X